A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments
Conditions
- Relapsed/Refractory Multiple Myeloma
- Multiple Myeloma
Interventions
Sponsor
Pfizer